Relocation of the
European Medicines Agency


Where the world comes to work



Dublin’s EMA bid boosted by the expansion of Luas light rail network across the city.

Britain’s decision to leave the European Union has meant that the European Medicines Agency (EMA) must relocate from its current home in London, and Dublin is just one of the major European cities bidding to host the agency after Brexit.

A city boasting excellent European and global connections is of paramount importance when considering the EMA’s relocation. Dublin is exactly that - a modern and thriving European capital with the infrastructure and transport links required by an international operation, such as the EMA.

Although Dublin is a compact city that’s easy to get around on foot, it is served well by a significant number of excellent public and private transport services, with the DART urban railway system, the highly networked Dublin Bus network, the comprehensive Irish Rail regional service and of course the Luas light rail network – a frequent tram service that connects Dublin city centre with suburbs in the south and south-west of the city.

Last year, the Luas network alone carried 34.2 million passengers, and this number will increase following completion of the ‘Luas Cross City’ project by the end of 2017. The project will be an extension of the service, creating an interchange that will facilitate an additional 10 million passenger journeys per year. As one of the largest capital investment projects undertaken by the government, the Cross City line will incorporate thirteen new stops, eight of which will be in the core city-centre area.

The expansion of the Luas light rail network will make commuting in Dublin more efficient and accessible than ever. This represents yet another string to Dublin’s bow in its bid to host the EMA following Britain’s exit from the European Union. With the youngest population in Europe, great cultural diversity and an exceptional life sciences community, Dublin has become a hugely attractive location for global pharma, life sciences and technology companies that can provide the perfect new home for the EMA.

*Original Article -

Back to news